Comparison of the Effectiveness and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Newly Diagnosed Atrial Fibrillation

• Published in: The American journal of cardiology Vol. 120; no. 10; pp. 1813 - 1819
• Main Authors: Hernandez, Inmaculada, Zhang, Yuting, Saba, Samir
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 15.11.2017; Elsevier Limited
• Subjects: Administration, Oral; Aged; Anticoagulants; Anticoagulants - administration & dosage; Antithrombins - administration & dosage; Atrial Fibrillation - complications; Atrial Fibrillation - diagnosis; Atrial Fibrillation - drug therapy; Bleeding; Cardiac arrhythmia; Coagulation; Confidence intervals; Dabigatran - administration & dosage; Dose-Response Relationship, Drug; Embolism; Embolism - epidemiology; Embolism - prevention & control; Factor Xa Inhibitors - administration & dosage; Female; Fibrillation; Follow-Up Studies; Humans; Incidence; Ischemia; Male; Pennsylvania - epidemiology; Pyrazoles - administration & dosage; Pyridones - administration & dosage; Retrospective Studies; Risk; Rivaroxaban - administration & dosage; Safety; Stroke; Stroke - epidemiology; Stroke - etiology; Stroke - prevention & control; Treatment Outcome; Warfarin; Warfarin - administration & dosage

No studies have performed direct pairwise comparisons of the effectiveness and safety of warfarin and the new oral anticoagulants (NOACs) apixaban, dabigatran, and rivaroxaban. Using 2013 to 2014 claims from a 5% random sample of Medicare beneficiaries, we identified patients newly diagnosed with at...